Novartis AG

People-centered care for psoriasis and urticaria: Are we overlooking Internet addiction while only considering patients and physician settings? (2021) Schielein MC, Tizek L, Baeumer D, Hillmann E, Romer K, Wagner N, Zink A Journal article Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study (2020) Fasching P, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, et al. Journal article Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study (2020) D'Agostino M, Schett G, Lopez-Rdz A, Senolt L, Maldonado-Cocco J, Burgos-Vargas R, Naredo E, et al. Conference contribution Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial (2020) Baraliakos X, Gossec L, Pournara E, Jeka S, Blanco R, D'Angelo S, Schett G, et al. Conference contribution Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis (2020) Mease P, Van Der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola J, et al. Conference contribution EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al. Conference contribution Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al. Conference contribution Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (2020) Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Conference contribution Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Schober K, Mohr P, Kiecker F, et al. Conference contribution